Literature DB >> 14738639

Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 Years after treatment.

Milton H Goldrath1.   

Abstract

STUDY
OBJECTIVE: To compare the safety and efficacy of endometrial ablation using HydroThermAblator (HTA) and rollerball (RB) for treatment of menorrhagia.
DESIGN: Prospective, randomized, multicenter study (Canadian Task Force classification I).
SETTING: Nine private practice and university centers in the United States. PATIENTS: Two hundred seventy-six women. INTERVENTION: Hysteroscopic endometrial ablation with the HTA (187 women) and RB (89).
MEASUREMENTS AND MAIN RESULTS: Bleeding was assessed by pictorial diaries for 12 months, with patient interviews at 24 and 36 month. Amenorrhea rates, reduction of bleeding to normal levels or less, and patient satisfaction were tracked for 36 months, with rates in the HTA group of 53%, 94%, and 98% and in the RB group of 46%, 91%, and 97%, respectively.
CONCLUSION: Endometrial ablation with the HTA is a safe, effective, and durable treatment of menorrhagia in a broad patient population. It offers advantages over RB by reducing anesthesia requirements, reducing operating time, and eliminating risks of excessive fluid absorption, and is more easily learned.

Entities:  

Mesh:

Year:  2003        PMID: 14738639     DOI: 10.1016/s1074-3804(05)60157-0

Source DB:  PubMed          Journal:  J Am Assoc Gynecol Laparosc        ISSN: 1074-3804


  2 in total

1.  Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding.

Authors:  Radoslaw Wasiak; Anna Filonenko; David J Vanness; Kim U Wittrup-Jensen; Donald E Stull; Steven Siak; Ian Fraser
Journal:  Int J Womens Health       Date:  2012-07-12

2.  Endometrial resection and ablation techniques for heavy menstrual bleeding.

Authors:  Magdalena Bofill Rodriguez; Anne Lethaby; Mihaela Grigore; Julie Brown; Martha Hickey; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.